First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

BACKGROUND: In the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved OS versus EP alone in patients with extensive-stage (ES)-SCLC (HR 0.73 [95% CI 0.59–0.91; p = 0.0047]). Here we report results for a preplanned subgro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, Katsuyuki, Nishio, Makoto, Saito, Haruhiro, Okamoto, Isamu, Nakahara, Yasuharu, Hayashi, Hidetoshi, Hayama, Manabu, Laud, Peter, Jiang, Haiyi, Paz-Ares, Luis, Azuma, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134304/
https://www.ncbi.nlm.nih.gov/pubmed/33826027
http://dx.doi.org/10.1007/s10147-021-01899-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134304/
https://www.ncbi.nlm.nih.gov/pubmed/33826027
http://dx.doi.org/10.1007/s10147-021-01899-8

Ejemplares similares